Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CGC
CGC logo

CGC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.970
Open
0.947
VWAP
0.96
Vol
2.46M
Mkt Cap
426.00M
Low
0.945
Amount
2.36M
EV/EBITDA(TTM)
--
Total Shares
448.42M
EV
531.59M
EV/OCF(TTM)
--
P/S(TTM)
1.43
Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.
Show More

Events Timeline

(ET)
2026-06-30
09:00:00
Latest Data Shows Wendy's Borrow Rate Rises to 34.75%
select
2026-06-26 (ET)
2026-06-26
09:00:00
KULR Technology Group Borrow Rate Increases to 65.52%
select
2026-06-25 (ET)
2026-06-25
09:01:00
Angion Biomedica Borrow Rate Increases to 183.97%
select
2026-06-15 (ET)
2026-06-15
09:00:00
U.S. Stock Futures Surge as Investors Eye U.S.-Iran Peace Agreement
select
2026-06-15
07:31:00
Company Expects Positive Adjusted EBITDA in FY2027
select
2026-06-15
07:31:00
Company Reports Q4 Revenue of C$84.7M
select
2026-05-29 (ET)
2026-05-29
07:20:00
Canopy Growth Relaunches Tweed Brand in Germany
select
2026-05-07 (ET)
2026-05-07
08:00:00
Canopy Growth Expands Minor Cannabinoid Softgel Lineup
select

News

Fool
2.0
07-07Fool
Canopy Growth Faces Potential Reverse Stock Split Risk
  • Reverse Split Context: Canopy Growth's share price has fallen below $1, raising the possibility of another reverse stock split to meet Nasdaq listing requirements; if it remains under this threshold for 30 consecutive business days, it will receive a notification and must regain compliance within 180 days.
  • Historical Split Situation: The last reverse split occurred in December 2023 at a 1-for-10 ratio, but since then, the stock has plummeted by approximately 80%, indicating ongoing business struggles as it falls below the $1 mark again.
  • Market Performance Analysis: With a current market cap of $402 million and a daily trading volume of 1.6 million shares, the market reflects a lack of confidence in Canopy Growth's future growth, as evidenced by its gross margin of 17.48% failing to improve its financial situation.
  • Investor Caution: Although a reverse stock split may occur within the next 12 months, the company's continuous losses and poor growth prospects suggest that investors should be wary of holding this stock and consider other more promising growth stocks.
NASDAQ.COM
6.5
07-05NASDAQ.COM
Analyst's Bullish Outlook on Canopy Growth
  • Stock Price Decline: Canopy Growth's stock price has fallen back below $1 per share after a spring rally, indicating a lack of market confidence in its growth prospects, even as analysts remain optimistic about its future.
  • Analyst Price Target: The average analyst price target for Canopy Growth is currently $1.22 per share, approximately 27% above its current price, but this expectation fails to reflect the potential for a fourfold increase in its stock price.
  • Financial Performance: Although analysts noted that Canopy Growth would have achieved record adjusted EBITDA in its recently completed fiscal fourth quarter if not for one-time expenses, its FY2027 revenue growth estimate is only 5.1%, with adjusted EBITDA expected to remain negative, highlighting challenges in profitability.
  • Market Competition: Analysts suggest investors consider other U.S.-based cannabis companies with stronger fundamentals that are already profitable and licensed at the state level, indicating that Canopy Growth faces competitive pressures and investors should approach its optimistic forecasts with caution.
Fool
2.0
07-04Fool
Canopy Growth Stock Price Decline Analysis
  • Stock Price Decline: Canopy Growth surged during the spring marijuana stock rally but has since fallen back below $1 per share, indicating market concerns about its future prospects, which may impact investor confidence.
  • Analyst's Optimistic Outlook: Despite the average analyst price target being $1.22, 27% above the current price, Roth Capital's Bill Kirk maintains a bullish target of CAD 5 per share, reflecting strong confidence in the company's future.
  • Financial Performance Insights: Kirk noted that without one-time expenses, Canopy Growth would have achieved record adjusted EBITDA in its recently completed fiscal fourth quarter, highlighting positive developments in market share and cost control efforts.
  • Future Growth Challenges: Although Kirk's forecast is optimistic, the expected revenue growth of only 5.1% for FY2027 and continued negative adjusted EBITDA suggest significant challenges for the company to achieve a fourfold increase in stock price.
NASDAQ.COM
9.5
06-28NASDAQ.COM
Canopy Growth Earnings Analysis: Strong Medical Business
  • Medical Business Growth: Canopy Growth's medical marijuana segment reported a 27% revenue increase in Q4 of fiscal 2026 and a 17% increase for the full year, indicating strong performance that may solidify its leadership in the Canadian market.
  • Weak Recreational Business: Although the recreational marijuana segment grew 20% for fiscal 2026, the mere 1% growth in Q4 suggests that its outlook may not be as robust as anticipated, prompting investors to reassess future performance.
  • International Sales Volatility: International cannabis sales surged 68% in Q4 but fell 7% year-over-year, with supply chain issues cited as a significant hurdle, highlighting challenges and uncertainties in the global market.
  • Deteriorating Financial Health: Canopy Growth reported negative earnings again in fiscal 2026, with gross margins declining by 4 percentage points in Q4 and 6 percentage points for the full year, raising concerns about the company's overall financial health and prompting investor caution.
Fool
9.5
06-28Fool
Canopy Growth Reports Strong Growth in Medical Marijuana Business
  • Medical Marijuana Growth: Canopy Growth's medical marijuana revenue surged by 27% in Q4 of fiscal 2026 and 17% for the full year, demonstrating strong performance that solidifies the company's leadership in the Canadian market.
  • Weak Recreational Business: Although the recreational marijuana segment saw a 20% increase in fiscal 2026, the mere 1% growth in Q4 suggests that its outlook may not be as robust as anticipated, prompting caution among investors.
  • International Sales Fluctuations: International cannabis sales rose by 68% in Q4 but fell 7% year-over-year, with supply chain issues impacting performance and creating uncertainty about future prospects, thereby increasing investment risks.
  • Declining Gross Margins: The company's gross margin fell by 4 percentage points in Q4 and 6 percentage points for the full year, coupled with ongoing negative earnings and balance sheet recapitalization, indicating that investors should remain on the sidelines.
NASDAQ.COM
9.5
06-16NASDAQ.COM
Canopy Growth Reduces Debt and Reports Revenue Growth
  • Financial Stability Improvement: Canopy Growth achieved a 10% revenue growth in fiscal 2026 while reducing free cash outflow from CA$176.6 million to CA$69.1 million, indicating significant progress in financial management that is expected to lay the groundwork for future profitability.
  • Acquisition Integration Strategy: By acquiring MTL Cannabis for CA$125 million, Canopy has elevated its revenue ranking to the top in Canada's medical cannabis market; although the first half of fiscal 2027 will incur integration costs, the second half is expected to see margin expansion, enhancing competitive positioning.
  • International Market Expansion: Canopy's international net revenue grew by 68% in Q4 of fiscal 2026, driven by regulatory relaxations in Germany and increased acceptance of medical cannabis, indicating substantial long-term growth potential in the European market.
  • Future Growth Outlook: By the end of fiscal 2027, Canopy is expected to achieve positive adjusted EBITDA, marking a transition from a debt-laden entity to a cash-flow-positive leader, with a focus on expanding into international markets, particularly the U.S. and Europe.
Wall Street analysts forecast CGC stock price to rise
4 Analyst Rating
Wall Street analysts forecast CGC stock price to rise
1 Buy
2 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
1.03
Averages
2.52
High
5.90
Current: 0.000
sliders
Low
1.03
Averages
2.52
High
5.90
Alliance Global
Neutral
downgrade
AI Analysis
2026-06-16
Reason
Alliance Global
Price Target
AI Analysis
2026-06-16
downgrade
Neutral
Reason
Alliance Global lowered the firm's price target on Canopy Growth to C$1.60 from C$1.80 and keeps a Neutral rating on the shares after the company reported fiscal Q4 sales and EBITDA below the firm's estimates as Canadian adults use sales came in below expectations.
Canaccord
Buy
initiated
$2
2026-03-27
Reason
Canaccord
Price Target
$2
2026-03-27
initiated
Buy
Reason
Canaccord initiated coverage of Canopy Growth with a Buy rating and C$2 price target. Canopy is a leading cannabis company producing, distributing, and selling a "diverse range" of cannabis and cannabis-related products in key, global adult-use and medical cannabis markets, the analyst tells investors in a research note. The firm says the company's pivot from an asset-light, third-party supply model to an asset-right, in-house supply model will improve its global competitive positioning.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CGC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Canopy Growth Corp (CGC.O) is 20.37, compared to its 5-year average forward P/E of -4.23. For a more detailed relative valuation and DCF analysis to assess Canopy Growth Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.23
Current PE
20.37
Overvalued PE
6.79
Undervalued PE
-15.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-278.72
Current EV/EBITDA
-6.46
Overvalued EV/EBITDA
445.31
Undervalued EV/EBITDA
-1002.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.54
Current PS
1.14
Overvalued PS
6.63
Undervalued PS
0.46

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

how is cannibis securities doing today
Intellectia · 8 candidates
Market Cap: >= 100.00MPrice: >= $1.00Themes: The Cannabis IndustryMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
CGC logo
CGC
Canopy Growth Corp
511.04M
TLRY logo
TLRY
Tilray Brands Inc
803.02M
SNDL logo
SNDL
SNDL Inc
391.39M
VFF logo
VFF
Village Farms International Inc
328.97M
ACB logo
ACB
Aurora Cannabis Inc
201.89M
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.49B
list10 stocks up 5%
Intellectia · 371 candidates
Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
AGPU logo
AGPU
Axe Compute Inc
25.59M
ELPW logo
ELPW
eLong Power Holding Ltd
2.23M
TORO logo
TORO
Toro Corp
112.81M
NMAX logo
NMAX
Newsmax Inc
940.13M
BEEM logo
BEEM
Beam Global
32.13M
XNDU logo
XNDU
Xanadu Quantum Technologies Ltd
8.18B
Top stocks to buy between 1 and 2 dollors
Intellectia · 291 candidates
Region: USPrice: $1.00 - $2.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
SID logo
SID
Companhia Siderurgica Nacional SA
1.78B
IQ logo
IQ
iQIYI Inc
1.35B
GERN logo
GERN
Geron Corp
1.08B
AMC logo
AMC
AMC Entertainment Holdings Inc
938.30M
OPK logo
OPK
OPKO Health Inc
918.47M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
779.57M
what are the cheapest
Intellectia · 146 candidates
Price: $0.10 - $5.00Rsi Category: moderateRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
QNCX logo
QNCX
Quince Therapeutics Inc
10.20M
GPUS logo
GPUS
Hyperscale Data Inc
54.64M
BURU logo
BURU
NUBURU Inc
29.16M
PMNT logo
PMNT
Perfect Moment Ltd
13.69M
OPTT logo
OPTT
Ocean Power Technologies Inc
83.41M
GUTS logo
GUTS
Fractyl Health Inc
73.79M
top 5 penny stocks?
Intellectia · 91 candidates
Market Cap: 50.00M - 2.00BRegion: USPrice: $0.10 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $0.00 - $150.00Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
RXT logo
RXT
Rackspace Technology Inc
409.23M
KOS logo
KOS
Kosmos Energy Ltd
1.03B
IOVA logo
IOVA
Iovance Biotherapeutics Inc
1.14B
GERN logo
GERN
Geron Corp
1.20B
TRX logo
TRX
TRX Gold Corp
516.12M
AQST logo
AQST
Aquestive Therapeutics Inc
481.91M
Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
stocks under $2 for day trade today
Intellectia · 158 candidates
Price: <= $2.00Volume: >= 500,000Price Change Pct: $-5.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PHIO logo
PHIO
Phio Pharmaceuticals Corp
12.06M
PLUG logo
PLUG
Plug Power Inc
2.84B
BURU logo
BURU
NUBURU Inc
56.42M
TIRX logo
TIRX
Tian Ruixiang Holdings Ltd
10.04M
JTAI logo
JTAI
Jet.AI Inc
5.61M
BTBT logo
BTBT
Bit Digital Inc
563.19M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
stocks to buy for 1.19 i only have $10
Intellectia · 105 candidates
Price: <= $1.19Weekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ASST logo
ASST
Strive Inc
1.11B
UP logo
UP
Wheels Up Experience Inc
624.57M
CAN logo
CAN
Canaan Inc
498.64M
CGC logo
CGC
Canopy Growth Corp
460.70M
DVLT logo
DVLT
Datavault AI Inc
433.82M
BYND logo
BYND
Beyond Meat Inc
424.50M

Whales Holding CGC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Canopy Growth Corp (CGC) stock price today?

The current price of CGC is 0.9651 USD — it has increased 1.58

What is Canopy Growth Corp (CGC)'s business?

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

What is the price predicton of CGC Stock?

Wall Street analysts forecast CGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGC is2.52 USD with a low forecast of 1.03 USD and a high forecast of 5.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Canopy Growth Corp (CGC)'s revenue for the last quarter?

Canopy Growth Corp revenue for the last quarter amounts to 71.25M USD, increased 9.56

What is Canopy Growth Corp (CGC)'s earnings per share (EPS) for the last quarter?

Canopy Growth Corp. EPS for the last quarter amounts to -0.41 USD, decreased -52.33

How many employees does Canopy Growth Corp (CGC). have?

Canopy Growth Corp (CGC) has 1128 emplpoyees as of July 08 2026.

What is Canopy Growth Corp (CGC) market cap?

Today CGC has the market capitalization of 426.00M USD.